O
27.14
-2.05 (-7.02%)
| Previous Close | 29.19 |
| Open | 29.14 |
| Volume | 872,235 |
| Avg. Volume (3M) | 3,827,416 |
| Market Cap | 2,175,540,224 |
| Price / Book | 2.57 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 0.30% |
| Current Ratio (MRQ) | 15.22 |
| Operating Cash Flow (TTM) | -124.83 M |
| Levered Free Cash Flow (TTM) | -70.86 M |
| Return on Assets (TTM) | -27.44% |
| Return on Equity (TTM) | -41.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Olema Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 98.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (Stifel, 76.86%) | Buy |
| Median | 45.00 (65.81%) | |
| Low | 38.00 (HC Wainwright & Co., 40.02%) | Buy |
| Average | 43.67 (60.91%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 22.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Mar 2026 | 38.00 (40.01%) | Buy | 16.00 |
| Stifel | 11 Feb 2026 | 48.00 (76.86%) | Buy | 23.65 |
| UBS | 07 Jan 2026 | 45.00 (65.81%) | Buy | 27.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Olema Oncology to Participate in Upcoming Investor Conferences |
| 03 Feb 2026 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Jan 2026 | Announcement | Olema Oncology Announces Departure of Chief Operating and Financial Officer |
| 05 Jan 2026 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Jan 2026 | Announcement | Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |